Response surface methods for the study of multiple-agent interaction allow one to model all of the information present in full concentration-effect data sets and to visualize and quantify local regions of synergy, additivity, and antagonism. In randomized wells of 96-well plates, Aspergillus fumigatus was exposed to various combinations of amphotericin B, micafungin, and nikkomycin Z. The experimental design was comprised of 91 different fixed-ratio mixtures, all performed in quintuplicate. After 24 h of drug exposure, drug effect on fungal viability was assessed using the tetrazolium salt 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide} (XTT) assay. First, we modeled each fixed-ratio combination alone using the four-parameter Hill concentration-effect model. Then, we modeled each parameter, including the 50% inhibitory concentration (IC 50 ) effect, versus the proportion of each agent using constrained polynomials. Finally, we modeled the three-agent response surface overall. The overall four-dimensional response surface was complex, but it can be explained in detail both analytically and graphically. The grand model that fit the best included complex polynomial equations for the slope parameter m and the combination index (equivalent to the IC 50 for a fixed-ratio concentration, but with concentrations normalized by the respective IC 50 s of the drugs alone). There was a large region of synergy, mostly at the nikkomycin Z/micafungin edge of the ternary plots for equal normalized proportions of each drug and extending into the center of the plots. Applying this response surface method to a huge data set for a three-antifungal-agent combination is novel. This new paradigm has the potential to significantly advance the field of combination antifungal pharmacology.
Invasive aspergillosis is a major cause of morbidity and mortality in highly immunocompromised persons (15) . Risk factors for invasive aspergillosis include prolonged neutropenia, hematopoietic stem cell transplantation, solid organ transplantation, advanced AIDS, and chronic granulomatous disease (22) . The expansion of the number of antifungal drugs with different modes of action that are used in the clinic and that are at preclinical stages of development has generated significant interest in combination antifungal therapy for invasive aspergillosis (4, 11, 13, 14, 25) . The recent sequencing of the Aspergillus fumigatus genome will provide additional tools for the identification of novel targets for drug development (19) . These important advances create a greater need to model effectively the combination of antifungal agents in vitro and in vivo.
In the past, various approaches to the assessment of synergy, additivity, and antagonism have been developed. They include older graphical isobologram methods and newer statistical response surface methods. The older methods are mostly limited to two-agent interactions; however, several statistical response surface methods can be used for three-agent and higher order combinations. Response surface methods, in particular, allow one to model and interpret all of the information present in the full concentration-effect data set; to visualize local regions of synergy, additivity, and antagonism; and even to quantify the degree of synergy or antagonism.
In the current study, we modeled the in vitro effect of amphotericin B, micafungin, and nikkomycin Z on A. fumigatus. These agents have distinct modes of action. Amphotericin B principally acts by binding to ergosterol, the major component of fungal cell membranes, leading to the disruption of the membrane and leakage of cellular metabolites and eventually cell death (21) . The echinocandin, micafungin, inhibits glucan synthase, leading to the depletion of ␤(1-3) glucan, a fungal cell wall constituent (10) . Nikkomycin Z is an investigational drug that inhibits synthesis of chitin, also a fungal cell wall constituent (17) . We demonstrated a complex set of interactions among these agents. Compared to simpler models, our final model fit the data the best and gave useful information about the interaction of the three drugs.
(Preliminary results were presented at the International Society of Anti-Infective Pharmacology [ISAP] meeting, Washington, DC, December 2005, and at the 2006 American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Baltimore, MD [1a] .)
MATERIALS AND METHODS

Tetrazolium salt 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide} (XTT) assay. (i) Preparation of conidia.
A clinical isolate of A. fumigatus previously used in experimental aspergillosis (18, 22) was used in all studies. Using standard CLSI methods (18a), the 24-and 48-h MICs of the isolate for amphotericin B were 0.5 g/ml, the MICs for micafungin were Յ0.03 g/ml, and the MICs for nikkomycin Z were 64 and 128 g/ml at 24 and 48 h, respectively. MICs correspond to the lowest drug concentration that will inhibit fungal growth based on visual inspection.
Conidia were plated on Sabouraud BHI slants with chloramphenicol and gentamicin (Becton Dickinson, MD), incubated for 7 to 10 days at room temperature, and harvested by washing the slant with 10 ml of 0.05% Tween 20 in normal saline (NS). The conidial suspension was then passed through a 100-m filter, counted on a hemacytometer, and diluted to 2.0 ϫ 10 6 CFU/ml. Conidia were then diluted 1:50 in MOPS (morpholinepropanesulfonic acid)-buffered RPMI (pH 7.0). In each experiment, the number of CFU per milliliter was verified by plating serial dilutions in duplicate on Sabouraud Dextrose Emmons plates and counting colonies 2 days later.
(ii) Preparation of drugs. Commercial amphotericin B deoxycholate (McKesson, West Seneca, NY) was reconstituted in dimethyl sulfoxide (DMSO) (100%) and diluted 1:50 in MOPS-buffered RPMI (pH 7.0) to generate a concentration of 4.44 g/ml. Micafungin (Fujisawa, Deerfield, IL) was reconstituted in NS (5 mg/ml) and then diluted 1:50 to generate a concentration of 2.22 g/ml in 2% DMSO MOPSbuffered RPMI (pH 7.0). Nikkomycin Z (provided by Thomas Walsh, NIH, Bethesda, MD) was reconstituted in MOPS-buffered RPMI (pH 7.0) to generate a concentration of 2.22 mg/ml.
(iii) Drug combinations. Solutions of each drug alone were prepared as well as the various fixed-ratio binary and ternary mixtures. Drug dilutions in 2% DMSO MOPS-buffered RPMI were first made sequentially by 3.33-fold in tubes in 96-tube racks. The tubes were then randomized into new racks; and the drug solutions (100 l/well) were applied to the wells in flat-bottom 96-well plates. Our group found that systematic growth patterns can be found in routine nonrandomized growth experiments; the additional randomization step is useful for eliminating systematic biases (6) .
Five experiments, which we will refer to as experiments A to E, were performed separately. Each design point in each experiment was replicated in quintuplicate; thus, each stack included five 96-well plates, each with the same set of drug concentrations. We analyzed a total of 91 different fixed ratios (7 in experiment A, and 21 in each of experiments B through E), with 11 serial drug dilutions per fixed ratio and control wells that contained conidia, medium, and vehicle without added drug. There was a total of 5,610 data points: 91 fixed ratios (each with 11 dilutions) plus 13 control columns, 1 in experiment A and 3 in each of experiments B through E, in quintuplicate, with the exclusion of 110 wells that could not be satisfactorily read.
For these experimental designs, the assumed potency ratio on a microgramper-milliliter basis used for micafungin-to-nikkomycin Z-to-amphotericin B was 1:1000:2. For example, a 1:4:2 ratio will correspond to a 1:4,000:4 fixed ratio of concentrations (on a microgram-per-milliliter basis).
(iv) Measurement of fungal viability. Following the addition of drug-containing medium to each well, the conidial suspension (100 l) was added (t ϭ 0 h). Control wells contained conidia, medium, and vehicle used to solubilize drug, without active drug. Blank wells consisted of medium only without conidia. Plates were incubated at 37°C, and the XTT assay was performed at 24 h essentially as previously described by Meletiadis et al. (16) , but with a minor adaptation. A stock solution of XTT (Sigma Chemical, St. Louis, MO) was dissolved in NS (1 mg/ml). A 10-mM solution of the electron-coupling agent menadione (Sigma Chemical) was prepared in acetone and then diluted 1:10 in NS. A working solution consisting of 4.0 ml XTT and 0.5 ml menadione was prepared immediately before use. Fifty microliters of the combination solution was added to each well, and plates were incubated for 2 h at 37°C. One hundred microliters of the supernatant was transferred to a new plate, and the optical density at 450 nm (OD 450 ) was determined by using a Labsystems Multiskan Plus plate reader. Final concentrations of XTT and menadione in each well were 200 g/ml and 25 M, respectively (16) .
An additional experiment was performed to ensure that the drugs did not, by themselves, affect the colorimetric readout of the assay. Amphotericin B (2.4 g/ml), micafungin (0.48 g/ml), and nikkomycin Z (120 g/ml) and the combination of all three drugs was added to medium in 96-well plates and serially diluted 3.33-fold 11 times. None of the wells contained A. fumigatus conidia. Blanks contained medium alone. Plates were incubated at 37°C for 24 h followed by the addition of XTT-menadione and the determination of the OD 450. None of the drug concentrations alone or in combination affected the OD 450 (data not shown). Another reassurance that the drugs had no direct effect on the colorimetric readout was that when exposed to fungus, none of the drugs produced a concentration-effect curve with a right tail that drifted upward with increasing drug concentration.
(v) Statistical methods and results. For fitting models to data, we used SAS 9.1; for the graphs we used SigmaPlot version 9.0; and for some intermediary calculations, we used Microsoft Excel.
In SAS, we used the PROC NLIN procedure. In that procedure, we use the Gauss-Newton algorithm. The NOHALVE and CONVERGE PARM ϭ 1e
Ϫ8
options were used to facilitate convergence.
The procedure was run a first time using rough, graphic-based estimations of the parameters with appropriate constraints, and then those initial estimates were fine tuned and the procedure was rerun to minimize the objective function and have the procedure converge. We also tried to minimize the standard deviations of the parameter estimates.
Modeling. (i) Weighting. For weighting, we used the inverse of the predicted variances at each design point. As a representative example, Fig. 1 shows the double-logarithmic relationship between sample variance (y axis) and sample mean (x axis) for each quintuplicate design point for pooled experiments D and E; the best-fit regression line gives an estimate of the log variance versus log mean slope that we will call ⌽3 (here the estimated ⌽3 is 1.59).
Such a slope estimate was calculated for experiment A (⌽3 ϭ 2.12), experiment B (⌽3 ϭ 1.80), experiment C (⌽3 ϭ 2.15), and pooled experiments D and E (⌽3 ϭ 1.59). Experiments D and E were performed very close in time, and the slope estimates were very close, so we decided to pool them for the weighting.
The weighting factor (w) for each design point used was proportional to the reciprocal of the estimated variance, w ϭ (modeled effect)
Ϫ⌽3 . Finally, the sum of weights was calculated with the final fits and a correcting factor, F, was applied to each individual weight so that the sum of weights equals number of data points, N. F varied and had to be recalculated for each different model used.
This gave us the following weighting scheme:
(ii) Hill equation. The basis of our modeling work in this report is the fourparameter Hill concentration-effect model presented in equation 2 below.
In this equation, E is the measured effect (response), such as the cell mass (XTT absorbance) remaining in a culture vessel after drug exposure; C is concentration of drug; Econ is the measured effect at zero drug concentration; IC 50 is the median effective dose (or concentration) of drug; B% is the background of measured effect at infinite concentrations (expressed as a percentage of Econ); and m is a slope parameter. When m has a negative sign, the curve falls with an increasing drug concentration; when m is positive, the curve rises with an in-FIG. 1. Variance versus mean plot to estimate weighting factor.
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creasing drug concentration. When the absolute value of m is high (Ͼ5), the sigmoidal curve drops or rises rapidly; when it is low (Ͻ1), the sigmoidal curve drops or rises gradually. We used three distinct approaches to model the data, with each sequential approach being more complex and comprehensive than the previous one. The three methods were mathematically consistent with each other, but more statistical rigor accompanied the more complex approaches.
(iii) First approach: simple Hill model. First, we modeled each fixed-ratio combination alone by fitting the four-parameter Hill concentration-effect model described in equation 2 above to each set of single agent and each set of fixed-ratio combination concentration-effect data (91 individual curves). We allowed one Econ for each of the five experiments, and one IC 50 , m and B% per fixed-ratio concentration-effect curve; therefore, we tabulated 278 parameter estimates.
(iv) Second approach: modified CI 50 approach. For the second approach (1), the transformed x axis is C 1 /IC 50,1 ϩ C 2 /IC 50,2 for a two-agent combination, or C 1 /IC 50,1 ϩ C 2 /IC 50,2 ϩ C 3 /IC 50,3 for a three-agent combination. A modified Hill model is then fit to the transformed data. The estimated IC 50 for a fixed ratio is then called the combination index at the 50% level (CI 50 ), which itself is a measure of Loewe synergy (CI 50 Ͻ 1), Loewe antagonism (CI 50 Ͼ 1), or Loewe additivity (CI 50 ϭ 1). Equation 3 was fit to data for a three-agent fixed-ratio combination:
with A being the total normalized amount of drugs as follows:
and C 1 , C 2 , and C 3 being the concentrations of drugs 1, 2, and 3, respectively, and IC 50,1 , IC 50,2 , and IC 50,3 being the median effective concentrations of drugs 1, 2 and 3, respectively. We allowed one Econ for each of the five experiments and one IC 50 or CI 50 , m, and B% per fixed-ratio concentration-effect curve; therefore, we tabulated 278 parameter estimates, the same as with the simple Hill model approach.
(v) Third approach: overall response surface approach. Our third data analysis approach was to fit an overall response surface to all of the data simultaneously. There was no really consistent pattern observed for B% estimated from the second approach with drug fractions, so we decided to fix B% at its estimated value for each fixed ratio for later analyses. In step 3A, the m's and CI 50 s estimated from the second approach were then modeled as a function of drug fractions by using the following constrained polynomials.
For m
and for CI 50
with X 1 being fractions of micafungin, X 2 fractions of nikkomycin Z, and X 3 fractions of amphotericin B:
All of the ␣, ␤, ␥, and ␦ terms are polynomial coefficients (estimatible parameters). The use of these polynomials and the general modeling paradigm is from 
RESULTS
The final polynomials, reduced in structure to insure that all parameters had confidence intervals not including 0, are presented in equations 11 and 12:
with X equal to the vector of specific ratios of the three drugs X 1 , X 2 , and X 3 (equations 7, 8, and 9 above) and with equal to the vector of parameters (polynomial coefficients for m and CI 50 ), None of the 35 parameter estimates in the final grand model had 95 percent confidence intervals encompassing zero, confirming that they were all useful for the characterization of the four-dimensional response surface. Figure 2 shows examples of fits with 95% confidence interval envelopes for the final fit of the grand model. The abscissa is A, the normalized sum of the drug amounts (except for the drugs alone where it is the drug concentration), and the ordinate is the absorbance from the XTT assay. The observed data, predicted values, and upper and lower population 95% confidence interval envelopes are shown. Figure 3 shows observed data (absorbances obtained from the experiment) versus the absorbances predicted from the grand model. Figure 4 shows the m estimates from the modified CI 50 method versus the m estimates from the grand model to give an idea of the quality of the fit and the absence of bias. Figure 5 shows the CI 50 s estimated from the modified CI 50 method versus the CI 50 s estimated from the grand model to give an idea of the quality of the fit and the absence of bias.
In Fig. 6 , the upper panels include traditional isobolograms at the 50% effect level. The lower panels include plots of the CI 50 s (log scale) versus drug fraction (X 1 , X 2 , and X 3 from 1806 BRUN ET AL. ANTIMICROB. AGENTS CHEMOTHER.
on October 30, 2017 by guest http://aac.asm.org/ equations 7 to 9). This figure shows that we have irregular isobols, with zones of antagonism and zones of synergy for the same two drug mixtures at different ratios when we apply the simple Hill approach or the modified CI 50 approach. Note that the isobols from the grand model in the upper panels and the corresponding curves in the lower panels are also asymmetrical. The ability to model asymmetrical isobols is a special unique property of our response surface modeling paradigm. The estimates of the parameters from the grand model are given in Tables 1 and 2 Figure 7 shows the CI 50 s predicted with the grand model for the whole surface in a ternary plot. We also show the contours for different CI 50 levels.
Finally, Fig. 8 shows the CI 10 , CI 25 , CI 50 , CI 75 , and CI 90 predicted with the grand model in the same type of ternary plot as that for Fig. 7 . 
DISCUSSION
Our novel modeling approach was able to fit the data properly and gave us insights into the synergy and antagonism patterns for the different proportions of each of three antifungal drugs. The full model that fit the best included a polynomial equation for m and a complex polynomial equation for CI 50 . Our comprehensive modeling paradigm had the significant advantage over the simple Hill model approach and the modified CI 50 approach of providing an overall fit to all the data points simultaneously. The overall fit resulted in a smooth surface and smooth irregular isobols, while not allowing any single fixed-ratio concentration profile to unduly influence the final result.
For combinations of micafungin, nikkomycin Z, and amphotericin B at the 50% effect level, we observed the most synergy with the combination of micafungin and nikkomycin Z at a normalized ratio of 3:7 (3:7,000 ratio of concentrations), with no amphotericin B in the mixture. It may be useful to study this particular binary combination at this particular fixed ratio in future in vivo studies (after taking into account the pharmacokinetic profiles of each agent in the specific study species). This synergy zone was indicated by CI 50 levels of approximately 0.2, indicating a fivefold increase in the activity of the mixture over the additivity prediction. The maximum antagonism was indicated by a CI 50 of approximately 2 or a decrease of the activity by half relative to the additivity prediction.
At the other CI levels, the most intense synergy was observed with the normalized ratios of 0/96/4 (micafungin/ nikkomycin Z/amphotericin B) for CI 10 , ratios of 0/92/8 for CI 25 terms, including higher order terms. A glance at Fig. 4 , 5, and 6 might give the impression that more complex polynomials might increase the overall goodness of fit of the grand model to the data. However, our group made a decision, based upon working with several complex three-agent data sets, that the maximum practical complexity for the two critical polynomials should be that of equations 5 and 6. The decision was based on (i) lack of reproduceability of very complex patterns for the m and CI 50 parameters, (ii) problems in interpreting the meaning of each individual coefficient in a very large set of polynomial coefficients, (iii) biases that different experimental designs would impose upon the numbers and orders of estimated sets of polynomial coefficients, and (iv) the lack of practical interest by biologists in an extremely complex but mostly empirical model. Our compromise approach is to limit the maximum complexity of the two critical polynomials to equations 5 and 6. Note that the polynomial expressions used finally in the grand model included only nine polynomial coefficients for the m expression, and six coefficients for the CI 50 expression. Of the 20 total possible polynomial coefficients for the m and CI 50 expressions, only 15 were retained, after eliminating coefficients whose 95% confidence intervals included zero in step 3A.
Combination antifungal studies in vitro have been largely restricted to testing only two agents at a time by using a checkerboard method using the fractional inhibitory concentration (FIC). (20) . Using this approach, the interaction between caspofungin and either voriconazole or amphotericin B was either synergistic, additive, or subadditive among clinical isolates of Aspergillus species, but no antagonism was observed (3, 20) . This FIC method is ideally suited to evaluating a large number of fungal isolates (e.g., for epidemiologic studies). While the MIC provides a single value corresponding to the lowest concentration of drug that totally inhibits fungal growth, it provides limited information about how different concentrations of a given antifungal agent affect fungal growth to various degrees. The concentration-effect relationship of antifungals extends over a broad range of concentrations instead of growth versus no growth (28) . The FIC index, which is derived from MIC data, provides limited understanding of potentially complex interactions among two or more antifungal agents. For example, two drugs may have synergy within a specific concentration range and additivity or even antagonism at another concentration range. A surface response approach, in which all drug effects alone and in combination and not just the MIC effect are modeled, overcomes some of these limitations (28) . However, the fundamental mathematical origin of the FIC index approach and the sophisticated response surface approach described in the report are in fact the same (12). The combination of an echinocandin and nikkomycin Z may be attractive since they target different fungal cell wall constituents. Chiou et al. (2) showed that micafungin and nikkomycin Z had marked in vitro synergistic activity against A. fumigatus as determined by the checkerboard inhibitory assay and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] viability assays. Time-sequenced light and electron microscopic studies demonstrated marked transformation of hyphae to blastospore-like structures in the presence of micafungin plus nikkomycin Z, while fungi treated with a single drug showed partial recovery at 24 h. Other studies have also reported in vitro synergy between nikkomycin Z and echinocandins against A. fumigatus (7, 26), but not between nikkomycin Z and either azoles or amphotericin B (7). Consistent with these studies, we noted a large region of synergy, starting at the nikkomycin Z/micafungin combinations for equal normalized proportions of each drugs and spreading toward the center of the ternary plot, and a region of antagonism between nikkomycin Z and amphotericin B at a high nikkomycin Z/amphotericin B ratios.
Hope et al. (9) used a response surface model (8) to examine the interaction of amphotericin B and flucytosine for treatment of systemic candidiasis in mice. The combination was additive, meaning that the experimental effect did not deviate in a statistically significant manner from the null reference model (or additive surface) of the combined effect. We recently reported that the combination of amphotericin B and micafungin was more effective than either agent alone in prolonging survival in experimental aspergillosis in the p47
phoxϪ/Ϫ mouse model of chronic granulomatous disease (5). This study did not allow any conclusion about in vivo synergy, as a single-dose regimen was used for each drug. The same A. fumigatus isolate that was used in this in vivo study was used for in vitro modeling in the current report.
There are several limitations to our study. First, because of the intensive labor involved in this modeling approach, only a single A. fumigatus isolate was used. The interactions we observed may be substantially different for Aspergillus isolates with different susceptibility profiles to the antifungal agents we modeled. For example, modeling combination regimens against Aspergillus terreus, a strain with intrinsic resistance to amphotericin B (23, 24, 29) , may produce entirely different interactions. We examined the effect of drug exposure at only one time point for a 24-h continuous drug exposure, and therefore, we cannot address potential time-dependent drug interactions. An inherent limitation of in vitro studies is that they cannot model the complex pharmacokinetics and host inflammatory response that occur in vivo. The presence or absence of ischemic necrosis will affect the local inflammatory response, tissue oxygen content, tissue pH, and drug delivery to the infected site, all of which may influence the clinical efficacy of antifungal regimens (27, 30) . Therefore, results of in vitro modeling should not be directly extrapolated to the clinical setting. However, detailed in vitro modeling will provide the basis for the prioritization of promising drug combinations for evaluation in animal models as well as for the optimization of dosing. This approach may be particularly useful if one of the drugs has significant potency but also substantial toxicity (e.g., amphotericin B). A combination regimen involving synergistic agents may enable us to reduce the dose of the toxic drug and have an antifungal effect equal or superior to that of any of the agents used alone.
APPENDIX
The ratios and drug concentrations normalized by the IC 50 estimates for each agent and all experiments are shown in Table A1 . 
